Clinical Trial Detail

NCT ID NCT00471497
Title A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENESTnd)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

chronic myeloid leukemia

Therapies

Nilotinib

Imatinib

Age Groups: adult senior

No variant requirements are available.